Lilly’s VERVE-102 Shows Durable LDL-C Reduction
Indianapolis, Indiana, USA, May 25, 2026 Eli Lilly and Company has announced positive Phase 1b clinical results for VERVE-102,...
coronary artery disease
Advertisement
Tempus Launches AI Prostate Test for Advanced Cancer
Chicago, Illinois, USA – May 21, 2026 Tempus AI, Inc., a leader in artificial intelligence and precision medicine, announced...
Bayer Gains FDA Priority Review for Kerendia
WHIPPANY, N.J., May 21, 2026 Bayer has announced that the U.S. Food and Drug Administration (FDA) has granted Priority...
Reflow Medical Reports Positive Six-Month Spur Elute Coronary Study Results
SAN CLEMENTE, Calif., May 20, 2026 Reflow Medical, Inc. has announced encouraging six-month clinical results from its DEEPER CORONARY...
Abbott Ultreon 3.0 AI Imaging Gains FDA, CE Approval
ABBOTT PARK, Illinois, USA, April 28, 2026 Abbott has announced that its next-generation Ultreon™ 3.0 AI-powered coronary imaging platform...
Advertisement
